(Adnkronos) - "Con esperienza ultra ventennale in reumatologia AbbVie porta in quest’area di cura l’approccio di migliorare gli standard di cura e i risultati per i pazienti. Nello specifico per il Lupus eritematoso sistemico è impegnata a sviluppare un ulteriore strumento per rispondere alle esigenze dei pazienti. In particolare il nostro inibitore di Jak è in corso di sperimentazione clinica er
Category
🗞
NewsTranscript
00:00AbbVie is a global biopharmaceutical company, based on research, focused on patients and
00:10strongly devoted to innovation, with the aim of bringing a significant impact to the lives
00:16of patients and focusing on therapeutic areas of which it has great experience, such as
00:22immunology, oncology, virology, neurosciences, ophthalmology and aesthetic medicine.
00:28We are present in the world in more than 70 countries, with about 47,000 employees.
00:34In Italy, the history of AbbVie is a long one.
00:37We have been present since 1949 with Abbott, AbbVie was born in 2013 as a spin-off of Abbott
00:45and today has about 1,700 employees in Italy.
00:49Half of these are working, are involved in the productive pole of Campo Verde, which
00:55is an eye-catcher for us.
00:58The company has invested a lot in the pole of Campo Verde to bring it to very high standards
01:05of competitiveness and environmental sustainability.
01:08And these standards have allowed us to bring to our country the production of many active
01:14pharmaceuticals that AbbVie makes available to the world.
01:17AbbVie is an ultraventricular experience in rheumatology and in this therapeutic area
01:23the approach of improving the standards of care and improving the results for patients
01:30who suffer from rheumatological diseases.
01:33Specifically, systemic rheumatoid lupus oles is an extremely complex autoimmune disease,
01:40characterized by the production of autoantibodies that can affect in a varied and heterogeneous
01:48way different organs and systems.
01:50The pulmonary system, the skeletal muscle system, the acute system, the central nervous system.
01:56Clearly, the symptoms vary depending on the type of narrow organ involved.
02:02It has an extremely unpredictable chronic course.
02:05Precisely for this reason, the unsatisfied need is very strong and AbbVie is committed
02:12to developing a possible further tool for doctors to respond to the needs of patients
02:19who suffer from this pathology.
02:21Specifically, our inhibitor of JAK, Upatacitinib, is currently under clinical experimentation
02:29in this context.
02:31Upatacitinib is our inhibitor of JAK and is the result of the effort, research and internal
02:36development of AbbVie.
02:37Upatacitinib is an irreversible selective inhibitor of JAK and is currently approved
02:43and imbibed in a series of immunological pathologies.
02:46Rheumatoid arthritis, archituzent spondylitis, psoriasis arthritis, ulcerative colitis and
02:53atopic dermatitis.
02:54We remain confident in the expected results of the molecule in the development program
03:00of systemic rheumatoid lupus oles.
03:02Among other things, Upatacitinib is currently being studied in two other immunological pathologies,
03:09vitiligin and alopecia areata.
03:12AbbVie is a company strongly devoted to research and development.
03:15In Italy, we have 78 clinical studies involving about 400 experimental centers.
03:22In general, AbbVie's research commitment in 2024 was equal to about 13 billion dollars,
03:29which represents an increase of 66.66% compared to the commitment of 2023.